

#723  
K  
9-27-01

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 20618-000600US  
Client Reference No.: N9-59

Assistant Commissioner for Patents  
Washington, D.C. 20231

On September 11, 2001

By: [Signature]

RECEIVED

SEP 25 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory S. Hageman

Application No.: 09/511,008

Filed: February 22, 2000

For: Diagnostics and Therapeutics for  
Arterial Wall Disruptive Disorders

Examiner: Q. Janice Li

Art Unit: 1632

**Response to Restriction Requirement &  
Preliminary Amendment**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed July 5, 2001 in the above-referenced application, Applicants provisionally elect Group II claims with traverse, for further prosecution in the subject application. Applicants also provisionally elect with traverse the species of drusen associated markers, elastin. Claims 1-10, 12, 19, 20, 36, and 37 read on the elected species. The grounds for the traverse are stated below.

Prior to examination of the subject application, please enter the following amendments and remarks.

IN THE CLAIMS

Please amend the claims as follows. A marked-up version of all elected claims is shown in the attached Appendix.

8. (Amended) The method of claim 1, wherein said marker is the presence of drusen in the subretinal pigmented epithelial (sub RPE) space.



B1